Giampaolo Bianchini, Head of the Translational and Immunotherapy Research Group at the San Raffaele Scientific Institute – Milan, shared on X:
“IMpassion030 just out in JAMA! A negative trial, but a crucial lesson:
In TNBC (as in many solid tumors), peri-operative chemo-immunotherapy is more effective than adjuvant chemo-immunotherapy.”
Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical Trial | Breast Cancer | JAMA | JAMA Network
Authors: Michail Ignatiadis, Andrew Bailey, Heather McArthur, Sarra El-abed, Evandro de Azambuja, Otto Metzger, Stephen Y. Chui, Max Dieterich, Thomas Perretti, Esther Shearer-Kang, Luciana Molinero, Günther G. Steger, Jacek Jassem, Soo Chin Lee, Michaela Higgins, Jose Zarba, Marcus Schmidt, Henry Gomez, Angel Guerrero Zotano, Luca Moscetti, Joanne Chiu, Elisabetta Munzone, Noa Efrat Ben-Baruch, Emilio Bajetta, Shinji Ohno, Seock-Ah Im, Gustavo Werutsky, Einav Nili Gal-Yam, Xavier Gonzalez Farre, Ling-Ming Tseng, William Jacot, Oleg Gluz, Zhimin Shao, Yaroslav Shparyk, Anastasia Zimina, Eric Winer, David A. Cameron, Giuseppe Viale, Shigehira Saji, Richard Gelber, Martine Piccart
